Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR
Authors:
- Claire E. WainwrightCWClaire E. Wainwright
- J. Stuart ElbornJEJ. Stuart Elborn
- Bonnie W. RamseyBRBonnie W. Ramsey
- Gautham MarigowdaGMGautham Marigowda
- Xiaohong HuangXHXiaohong Huang
- Marco CipolliMCMarco Cipolli
- Carla ColomboCCCarla Colombo
- Jane C. DaviesJDJane C. Davies
- Kris De BoeckKBKris De Boeck
- Patrick A. FlumePFPatrick A. Flume
- Michael W. KonstanMKMichael W. Konstan
- Susanna A. McColleySMSusanna A. McColley
Top Cited Papers
Open Access
- 16 July 2015
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 373 (3) , 220-231
Abstract
Cystic fibrosis is a life-limiting disease that is caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) protein activity. Phe508del is the most common CFTR mutation. We conducted two phase 3, randomized, double-blind, placebo-controlled studies that were designed to assess the effects of lumacaftor (VX-809), a CFTR corrector, in combination with ivacaftor (VX-770), a CFTR potentiator, in patients 12 years of age or older who had cystic fibrosis and were homozygous for the Phe508del CFTR mutation. In both studies, patients were randomly assigned to receive either lumacaftor (600 mg once daily or 400 mg every 12 hours) in combination with ivacaftor (250 mg every 12 hours) or matched placebo for 24 weeks. The primary end point was the absolute change from baseline in the percentage of predicted forced expiratory volume in 1 second (FEV1) at week 24. A total of 1108 patients underwent randomization and received study drug. The mean baseline FEV1 was 61% of the predicted value. In both studies, there were significant improvements in the primary end point in both lumacaftor–ivacaftor dose groups; the difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV1 ranged from 2.6 to 4.0 percentage points (PCFTR mutation. (Funded by Vertex Pharmaceuticals and others; TRAFFIC and TRANSPORT ClinicalTrials.gov numbers, NCT01807923 and NCT01807949.)Keywords
This publication has 29 references indexed in Scilit:
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Proceedings of the National Academy of Sciences, 2011
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proceedings of the National Academy of Sciences, 2009
- Determination of the Minimal Clinically Important Difference Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in Two Populations of Patients With Cystic Fibrosis and Chronic Pseudomonas aeruginosa Airway InfectionChest, 2009
- Cystic fibrosisThe Lancet, 2009
- Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practiceJournal of Cystic Fibrosis, 2008
- Clinical Use of Ibuprofen is Associated with Slower FEV1 Decline in Children with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Conformational and Temperature-sensitive Stability Defects of the ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator in Post-endoplasmic Reticulum CompartmentsJournal of Biological Chemistry, 2001
- Pulmonary function between 6 and 18 years of agePediatric Pulmonology, 1993
- Energy expenditure of patients with cystic fibrosisThe Journal of Pediatrics, 1987